USE OF UV SPECTROPHOTOMETRY IN ANALYSIS AND STANDARDIZATION OF 2-BENZOYLAMINO-N- [4- (4,6-DIMETHYLPYRIMIDIN-2-ILSULFAMOYL) -PHENYL] -BENZAMIDE SUBSTANCE

Abstract

Borderline neuropsychiatric disorders firmly hold a leading position in a large group of mental illnesses, among which neuroses occupy a significant place. The increasing number of patients with diseases associated with neuropsychiatric disorders makes the search and introduction of highly effective anxiolytics and antidepressants into medical practice increasingly important. In parallel with the search for medicinal substances with such pharmacological properties, it is necessary to resolve issues of standardization and quality control. One of these drugs may be a new synthetic derivative of ortho-benzoylaminobenzoic acid, which has antidepressant and anxiolytic effects. This compound was synthesized at the department of organic chemistry of the Pyatigorsk Medical and Pharmaceutical Institute under the leadership of professor Kodonidi I.P. Several biologically active compounds were synthesized - derivatives of o-benzoylaminobenzoic acid, one of which is 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide (laboratory code - PMFI-195) . Preliminary pharmacological studies of PMFI-195, carried out on the basis of the Federal State Budgetary Educational Institution of Higher Education of the Stavropol State Medical University of the Ministry of Health of Russia and the Federal State Budgetary Educational Institution of Higher Education of the North Caucasus Federal University, under the leadership of professor Manvelyan E.A., showed the promise of developing a drug based on the substance PMFI-195 for the treatment of such diseases such as depression, neuroses, psychopathy, neurosis-like and psycho-like states. Quality control and development of modern methods of pharmaceutical analysis is one of the basic stages of introducing pharmaceutical substances into production. This requires an in-depth study of physicochemical characteristics, as well as the selection and justification of methods of analysis and quality control of pharmaceuticals. substances. The results of the developed method for the qualitative determination by UV spectrophotometric method of a new quinosalinone derivative 2-benzoylamino-N-[4-(4,6-dimethylpyrimidin-2-ylsulfamoyl)-phenyl]-benzamide, which has anxiolytic and antidepressant activity, are presented.